MentionFox
Home › Executive changes › MoonLake Immunotherapeutics
Leadership changes · MLTX · SEC Form 8-K, Item 5.02

Leadership changes at MoonLake Immunotherapeutics (2026)

Before you join, sell to or invest in MoonLake Immunotherapeutics

MentionFox check on MoonLake Immunotherapeutics: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/moonlake-immunotherapeutics

Check MoonLake Immunotherapeutics before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about MoonLake Immunotherapeutics?

Who joined and who left MoonLake Immunotherapeutics (MLTX)? 1 departure reported from 2026-02-23 to 2026-06-09, each cited to the company's own filing.

Simon Sturge left the role of Director at MoonLake Immunotherapeutics, effective February 28, 2026. As of November 14, 2026, MoonLake Immunotherapeutics has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 23, 2026 to June 9, 2026, naming 1 departure (Form 8-K, February 23, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Chen Bihua also filed stake reports on 1 other company ↓

Sell to companies like MoonLake Immunotherapeutics? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
Out (departing)1
Latest filing2026-06-09

MoonLake Immunotherapeutics reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-23 to 2026-06-09. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as MoonLake Immunotherapeutics files it.

Also on the record for MoonLake Immunotherapeutics

DateRecordFigureOur pageSource
August 14, 2026Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc.5.3% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Cormorant Asset Management, LP4.35% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Deep Track Capital, LP9.74% of the class5%+ stakesSource
June 29, 2026Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P19.7% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Cormorant Asset Management, LP6.25% of the class5%+ stakesSource
April 2, 2026Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P22.3% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G, by Cormorant Asset Management, LP6.1% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC3.15% of the class5%+ stakesSource
November 12, 2025Stake report, Schedule 13G, by Deep Track Capital, LP6.46% of the class5%+ stakesSource
November 10, 2025Stake report, Schedule 13D/A, by BIOTECHNOLOGY VALUE FUND L P27.7% of the class5%+ stakesSource
November 5, 2025Stake report, Schedule 13G/A, by FMR LLC1.1% of the class5%+ stakesSource
October 1, 2025Stake report, Schedule 13G/A, by Chen Bihua3.14% of the class5%+ stakesSource

Selling to them or working with them? See who runs MoonLake Immunotherapeutics now and the warning signs.

Free to see. No signup.

Keep reading

More on MoonLake Immunotherapeutics and the records around it.

MoonLake Immunotherapeutics elsewhere on the record

Companies that share a holder

Want the whole picture on MoonLake Immunotherapeutics?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on MoonLake Immunotherapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on MoonLake Immunotherapeutics covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 14 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-06-09Reportednot named in the filing8-K, 2026-06-09
2026-02-23OutDirector2026-02-288-K, 2026-02-23

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads MoonLake Immunotherapeutics, as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to MoonLake Immunotherapeutics?

New leaders reset buying decisions — get the Full Report on MoonLake Immunotherapeutics: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch MoonLake Immunotherapeutics

Hiring for a seat like this?

Find people with the same kind of experience as the Director at MoonLake Immunotherapeutics, with the record behind each one.

Find candidates like Director at MoonLake Immunotherapeutics

Every change, in the filing's words

Filed 2026-06-09 · 8-K

Reported

Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Also stated in this filing

  • At the Annual Meeting, the Company's shareholders approved an amendment and restatement of the Company's 2022 Equity Incentive Plan (as so amended, the "Plan") to increase the number of Class A Ordinary Shares available for stock-based awards by 5,000,000 shares, remove liberal share recycling provisions, incorporate a one-year minimum vesting requirement, revise the non-employee director compensation limits set forth therein, specify the treatment of outstanding awards in the event of a change in control, extend the term of the Plan to June 4, 2036 and make certain other administrative changes.
Filed 2026-02-23 · 8-K

Departing: Simon Sturge, Director, effective 2026-02-28

On February 18, 2026, Simon Sturge notified the Board of Directors (the "Board") of the Company of his intent to resign as a member of the Board, effective as of February 28, 2026 (the "Effective Date").

Also stated in this filing

  • As of the Effective Date, the size of the Board will be reduced from six to five directors.
  • The Company and the Board extend their deepest gratitude to Mr. Sturge for his contributions to the Company.
  • In connection with Mr. Sturge's resignation, Dr. Jorge Santos da Silva was appointed Interim Chair of the Board, and Spike Loy was appointed as Lead Independent Director, both effective as of the Effective Date.

Tools for this story

Each opens in a new tab, filled in for MoonLake Immunotherapeutics. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/moonlake-immunotherapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
MoonLake Immunotherapeutics executive departure 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/moonlake-immunotherapeutics